DiaCarta’s Novel XNA Technology Rapidly Detects Raging New SARS-CoV-2 Variants
UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced the publication of a study entitled “A Rapid SARS-CoV-2 Variant Detection by Molecular-Clamping Based RT-qPCR” in MedRxiV that demonstrates the enhanced sensitivity and specificity using its proprietary XNA based Molecular Clamping Technology that uses innovative synthetic Xenonucleic acid molecular oligomers (XNA) that hybridize with target wild-type DNA sequences, acting as molecular clamps, to enable the accurate amplification of mutant sequences only, using quantitative real-time polymerase chain reactions (qPCR).
Learn more about DiaCarta’s Novel XNA Technology Rapidly Detects Raging New SARS-CoV-2 Variants.